Biorepository of Biospecimen Samples in Matched Healthy Control Participants and Participants Diagnosed With Diabetic Kidney Disease, Chronic Kidney Disease, or Type 2 Diabetes

You may be eligible if

• Cohort 1: Diabetic Kidney Disease
• Inclusion:
• 1. The participant is willing and able to provide written informed consent
• 2. The participant is willing and able to provide appropriate photo identification
• 3. Participants aged 18 to 85
• 4. Participants have been diagnosed with diabetic kidney disease. Enrollment preference for participants with stage 3 kidney disease but is not inclusionary.
• Exclusion:
• 1. Participants who are pregnant or are nursing
• 2. Participants with a known history of HIV, hepatitis, or other infectious diseases
• 3. Participants who have taken an investigational product in the last 30 days
• 4. Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
• Cohort 2: Chronic Kidney Disease
• Inclusion:
• 1. The participant is willing and able to provide written informed consent
• 2. The participant is willing and able to provide appropriate photo identification
• 3. Participants aged 18 to 85
• 4. Participants have been diagnosed with chronic kidney disease.
• Exclusion:
• 1. Participants who are pregnant or are nursing
• 2. Participants with a known history of HIV, hepatitis, or other infectious diseases
• 3. Participants who have taken an investigational product in the last 30 days
• 4. Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
• 5. Participants have been diagnosed with acute kidney disease or diabetic kidney disease
• Cohort 3: Type 2 Diabetes
• Inclusion:
• 1. The participant is willing and able to provide written informed consent
• 2. The participant is willing and able to provide appropriate photo identification
• 3. Participants aged 18 to 85
• 4. Participants have been diagnosed with type 2 diabetes.
• Exclusion:
• 1. Participants who are pregnant or are nursing
• 2. Participants with a known history of HIV, hepatitis, or other infectious diseases
• 3. Participants who have taken an investigational product in the last 30 days
• 4. Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
• 5. Participants have been diagnosed with type 1 diabetes
• Cohort 4: Healthy Matched The study will enroll participants considered healthy matched controls per the eligibility criteria. The healthy-matched controls must match each participant in the diseased cohorts by age (+/- 10 years).
• Inclusion:
• 1\. The participant is willing and able to provide written informed consent 2. The participant is willing and able to provide appropriate photo identification 3. Participants aged 18 to 85 4. Participants who are in generally good health are defined as: b. Participants may have a common/mild health condition(s) that are generally under control, including but not limited to: i. Hypertension, high cholesterol, asthma, anxiety, depression, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), allergies, eczema, migraines, osteoarthritis, sleep apnea, restless leg syndrome, and eye issues (e.g., myopia, astigmatism, etc.) ii. Participants with a previous diagnosis and have recovered from COVID-19 iii. Participants in general good health may also take nonsteroidal anti-inflammatory drugs (NSAIDS) (i.e., ibuprofen, Tylenol, aspirin, Excedrin) irregularly or semi-regularly due to conditions like headache, body aches, cold/flu treatment as long as the medications are not being used for the treatment of a major underlying condition.
• Exclusion:
• 1. Participants who are pregnant or are nursing
• 2. Participants with a known history of HIV, hepatitis, or other infectious diseases
• 3. Participants who have taken an investigational product in the last 30 days
• 4. Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
• 5. Participants not considered in general good health